![Michael Faerm](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Faerm
Keine laufenden Positionen mehr
Profil
Michael E.
Faerm is currently Chief Financial Officer at Atai Beckley, Inc. since 2026.
Former positions include Chief Financial Officer at Harpoon Therapeutics, Inc. from 2023 to 2024, Chief Financial & Accounting Officer at Viracta Therapeutics, Inc. from 2024 to 2025, Chief Financial Officer at Artiva Biotherapeutics, Inc. from 2021 to 2023, Chief Business Officer & Senior Vice President at Innoviva, Inc. from 2015 to 2018, Vice President at Merrill Lynch & Co., Inc. in 2000, Associate Director at Forest Laboratories, Inc. in 2006, Associate Director at Regeneron Pharmaceuticals, Inc. in 2004, Analyst at Credit Suisse Securities (USA) LLC from 2011 to 2013, and Analyst at Wells Fargo Securities LLC.
Education includes undergraduate studies at The Trustees of Columbia University in The City of New York, graduate studies at Stanford University, and an MBA from Harvard Business School.
Aktive Positionen von Michael Faerm
| Unternehmen | Position | Beginn |
|---|
Ehemalige bekannte Positionen von Michael Faerm
| Unternehmen | Position | Ende |
|---|---|---|
| VIRACTA THERAPEUTICS, INC. | Finanzdirektor/CFO | 05.02.2025 |
| HARPOON THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.03.2024 |
| ARTIVA BIOTHERAPEUTICS, INC. | Finanzdirektor/CFO | 01.03.2023 |
| INNOVIVA, INC. | Corporate Officer/Principal | 07.02.2018 |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | 01.01.2006 |
Ausbildung von Michael Faerm
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
64
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Credit Suisse Securities (USA) LLC (Broker)
 Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Provides brokerage services | Finance |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells drug products | Health Technology |
Regeneron Pharmaceuticals, Inc.
 Regeneron Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and commercializes medicines for diseases | Health Technology |
The Trustees of Columbia University in The City of New York
 The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Innoviva, Inc.
 Innoviva, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that manufactures respiratory drugs | Health Technology |
Wells Fargo Securities LLC
 Wells Fargo Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Merrill Lynch & Co., Inc.
 Merrill Lynch & Co., Inc. Investment ManagersFinance Provides wealth management, securities trading and sales, corporate finance and investment banking services | Finance |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage immunotherapy company that develops T-cell engagers to treat cancer and other diseases | Health Technology |
Artiva Biotherapeutics, Inc.
 Artiva Biotherapeutics, Inc. Pharmaceuticals: OtherHealth Technology Operates as a biotechnology company which develops natural killer cell-based therapies for patients suffering from autoimmune diseases and cancers | Health Technology |
Viracta Therapeutics, Inc.
 Viracta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for virus-associated cancers | Health Technology |
